These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36206307)

  • 21. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
    Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
    Shinde V; Cai R; Plested J; Cho I; Fiske J; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou H; Zhou B; Patel N; Massare MJ; Fix A; Spindler M; Thomas DN; Smith G; Fries L; Glenn GM
    Clin Infect Dis; 2021 Dec; 73(11):e4278-e4287. PubMed ID: 33146720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Broadly Reactive H2 Hemagglutinin Vaccines Elicit Cross-Reactive Antibodies in Ferrets Preimmune to Seasonal Influenza A Viruses.
    Reneer ZB; Skarlupka AL; Jamieson PJ; Ross TM
    mSphere; 2021 Mar; 6(2):. PubMed ID: 33692193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
    Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
    Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine-associated enhanced respiratory disease does not interfere with the adaptive immune response following challenge with pandemic A/H1N1 2009.
    Gauger PC; Loving CL; Lager KM; Janke BH; Kehrli ME; Roth JA; Vincent AL
    Viral Immunol; 2013 Oct; 26(5):314-21. PubMed ID: 24033080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
    van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.
    Wang S; Parker C; Taaffe J; Solórzano A; García-Sastre A; Lu S
    Vaccine; 2008 Jul; 26(29-30):3626-33. PubMed ID: 18538900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.
    Roman F; Clément F; Dewé W; Walravens K; Maes C; Willekens J; De Boever F; Hanon E; Leroux-Roels G
    Clin Vaccine Immunol; 2011 May; 18(5):835-43. PubMed ID: 21450978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.
    Lambe T; Spencer AJ; Mullarkey CE; Antrobus RD; Yu LM; de Whalley P; Thompson BA; Jones C; Chalk J; Kerridge S; Hill AV; Snape MD; Pollard AJ; Gilbert SC
    Pediatr Infect Dis J; 2012 Jun; 31(6):e86-91. PubMed ID: 22466328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E-rosette forming cells and humoral antibody titres in humans after vaccination with three different inactivated influenza virus vaccines A/USSR/92/77 (H1N1).
    Schmidt S; Süss J; Oehring H; Schmidt J
    Acta Virol; 1982 Dec; 26(6):466-73. PubMed ID: 6132540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial.
    Li YP; Li W; Liang XF; Liu Y; Huang XC; Li CG; Li RC; Wang JZ; Wang HQ; Yin WD
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1297-307. PubMed ID: 23134570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
    Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
    Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine.
    Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
    Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.